| pubmed-article:9205071 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9205071 | lifeskim:mentions | umls-concept:C2919114 | lld:lifeskim |
| pubmed-article:9205071 | lifeskim:mentions | umls-concept:C1512505 | lld:lifeskim |
| pubmed-article:9205071 | lifeskim:mentions | umls-concept:C0140279 | lld:lifeskim |
| pubmed-article:9205071 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:9205071 | lifeskim:mentions | umls-concept:C0018270 | lld:lifeskim |
| pubmed-article:9205071 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:9205071 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:9205071 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:9205071 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:9205071 | pubmed:issue | 13 | lld:pubmed |
| pubmed-article:9205071 | pubmed:dateCreated | 1997-7-25 | lld:pubmed |
| pubmed-article:9205071 | pubmed:abstractText | Retinoic acid receptor (RAR) alpha has been shown to play a role in retinoid-induced growth inhibition of human breast cancer cell lines that express the estrogen receptor (ER). The dogma in the field has been that ER-positive breast cancer cell lines respond to retinoid treatment because they express RAR alpha, whereas ER-negative breast cancer cell lines are refractory to retinoid treatment and have been thought to express little or no RAR alpha. We set out to test several ER-negative breast cancer cell lines for expression of RAR alpha protein and responsiveness to retinoids in growth inhibition assays. Of six ER-negative breast cancer cell lines that were tested, one (SK-BR-3) had high levels of RAR alpha protein as measured by ligand-binding immunoprecipitation (approximately 55 fmol/mg protein) and also displayed sensitivity to growth inhibition by retinoids (9-cis-retinoic acid; EC50, approximately 3 nM). These cells were more sensitive than an ER-positive cell line, T-47D, which expressed approximately 35 fmol RAR alpha/mg total protein (9-cis retinoic acid; EC50, approximately 50-100 nM). Another ER-negative cell line, Hs578T, also expressed RAR alpha (approximately 23 fmol/mg) and was sensitive to retinoid-induced growth inhibition, albeit to a lesser extent than SK-BR-3 or T-47D cells. In contrast, the other ER-negative cell lines tested expressed low (<10 fmol/mg) or no detectable levels of RAR alpha protein and also did not respond to retinoids in growth inhibition assays. A RAR alpha agonist displayed 100 times greater potency than a RARgamma agonist in growth inhibition of both T-47D and SK-BR-3 cells, suggesting RAR alpha involvement in the process. Furthermore, a RAR alpha antagonist completely abolished the growth inhibition induced by RAR agonists, implying that the activity of the agonists is exerted solely through RAR alpha, not RARgamma, which is also expressed in both cell lines. Additionally, although retinoid X receptor (RXR) compounds are weakly active in growth inhibition of the RAR alpha-positive cell lines, they markedly increased the growth-inhibitory activity of RAR ligands. RXR compounds also potentiated the action of the antiestrogen 4-hydroxytamoxifen to inhibit the growth of T-47D cells. These findings have clinical ramifications in that patients with ER-negative tumors that are RAR alpha positive may be candidates for retinoid therapy. Additionally, combinations of RXR ligands with RAR ligands (especially RAR alpha agonists) and/or antiestrogens may have utility in the treatment of breast cancer. | lld:pubmed |
| pubmed-article:9205071 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9205071 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9205071 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9205071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9205071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9205071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9205071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9205071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9205071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9205071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9205071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9205071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9205071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9205071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9205071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9205071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9205071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9205071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9205071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9205071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9205071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9205071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9205071 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9205071 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9205071 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:9205071 | pubmed:issn | 0008-5472 | lld:pubmed |
| pubmed-article:9205071 | pubmed:author | pubmed-author:HeymanR ARA | lld:pubmed |
| pubmed-article:9205071 | pubmed:author | pubmed-author:TengMM | lld:pubmed |
| pubmed-article:9205071 | pubmed:author | pubmed-author:FitzgeraldPP | lld:pubmed |
| pubmed-article:9205071 | pubmed:author | pubmed-author:AllegrettoE... | lld:pubmed |
| pubmed-article:9205071 | pubmed:author | pubmed-author:ChandraratnaR... | lld:pubmed |
| pubmed-article:9205071 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9205071 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:9205071 | pubmed:volume | 57 | lld:pubmed |
| pubmed-article:9205071 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9205071 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9205071 | pubmed:pagination | 2642-50 | lld:pubmed |
| pubmed-article:9205071 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:9205071 | pubmed:meshHeading | pubmed-meshheading:9205071-... | lld:pubmed |
| pubmed-article:9205071 | pubmed:meshHeading | pubmed-meshheading:9205071-... | lld:pubmed |
| pubmed-article:9205071 | pubmed:meshHeading | pubmed-meshheading:9205071-... | lld:pubmed |
| pubmed-article:9205071 | pubmed:meshHeading | pubmed-meshheading:9205071-... | lld:pubmed |
| pubmed-article:9205071 | pubmed:meshHeading | pubmed-meshheading:9205071-... | lld:pubmed |
| pubmed-article:9205071 | pubmed:meshHeading | pubmed-meshheading:9205071-... | lld:pubmed |
| pubmed-article:9205071 | pubmed:meshHeading | pubmed-meshheading:9205071-... | lld:pubmed |
| pubmed-article:9205071 | pubmed:meshHeading | pubmed-meshheading:9205071-... | lld:pubmed |
| pubmed-article:9205071 | pubmed:meshHeading | pubmed-meshheading:9205071-... | lld:pubmed |
| pubmed-article:9205071 | pubmed:meshHeading | pubmed-meshheading:9205071-... | lld:pubmed |
| pubmed-article:9205071 | pubmed:meshHeading | pubmed-meshheading:9205071-... | lld:pubmed |
| pubmed-article:9205071 | pubmed:meshHeading | pubmed-meshheading:9205071-... | lld:pubmed |
| pubmed-article:9205071 | pubmed:meshHeading | pubmed-meshheading:9205071-... | lld:pubmed |
| pubmed-article:9205071 | pubmed:meshHeading | pubmed-meshheading:9205071-... | lld:pubmed |
| pubmed-article:9205071 | pubmed:meshHeading | pubmed-meshheading:9205071-... | lld:pubmed |
| pubmed-article:9205071 | pubmed:meshHeading | pubmed-meshheading:9205071-... | lld:pubmed |
| pubmed-article:9205071 | pubmed:meshHeading | pubmed-meshheading:9205071-... | lld:pubmed |
| pubmed-article:9205071 | pubmed:meshHeading | pubmed-meshheading:9205071-... | lld:pubmed |
| pubmed-article:9205071 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9205071 | pubmed:articleTitle | Retinoic acid receptor alpha expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status. | lld:pubmed |
| pubmed-article:9205071 | pubmed:affiliation | Department of Retinoid Research, Ligand Pharmaceuticals, Inc., San Diego, California 92121, USA. | lld:pubmed |
| pubmed-article:9205071 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9205071 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9205071 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9205071 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9205071 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9205071 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9205071 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9205071 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9205071 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9205071 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9205071 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9205071 | lld:pubmed |
